Stay updated with breaking news from Protocol Co Chair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An unexpectedly high percentage of children, who were born with HIV and started treatment within 48 hours of life, exhibit biomarkers by 2 years of age that may make them eligible to test for medication-free remission, according to a multinational study published in Lancet HIV.
Dr Thesla-Palanee Phillips' research has made headlines worldwide. She chats to Spotlight about her career, her journey with IVF, and juggling her professional and personal life.
T-Guard®, under development by Xenikos B.V., is being studied in comparison to ruxolitinib in patients with Grade III or IV SR-aGHVDCARY, N.C., Ju...
Study Designed to Evaluate Whether T-Guard is Superior to Ruxolitinib in Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host...
Share: Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard ® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA Regulatory Submissions NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, today announced that it has reached agreement with the US Food and...